THRD Profile
Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing therapies for allergic and inflammatory diseases. The company's primary focus is on developing innovative treatments that target underlying mechanisms of these conditions, with an emphasis on providing solutions for chronic and debilitating disorders.
Third Harmonic Bio is advancing its lead product, THB001, an oral small-molecule inhibitor targeting the KIT protein. This compound is designed to address chronic urticaria, a dermatologic condition characterized by recurrent, itchy hives caused by mast cell activation. Additionally, THB001 is being developed for potential applications in treating related conditions affecting the airway and gastrointestinal tract, aiming to provide relief for patients suffering from similar inflammatory and allergic responses.
In its development pipeline, Third Harmonic Bio is committed to exploring and expanding its therapeutic offerings for a range of allergic and inflammatory diseases. The company's research efforts are focused on understanding and modulating the complex biological pathways involved in these conditions, with the goal of delivering effective, targeted treatments.
Founded in 2019 and headquartered in Cambridge, Massachusetts, Third Harmonic Bio was originally known as Project IGE, Inc. before rebranding in June 2019. The company leverages its expertise in drug development and its robust scientific foundation to drive progress in treating chronic allergic and inflammatory diseases, aiming to improve the quality of life for patients worldwide.
|
